Home  |  Contact

Cellosaurus MDA-MB-231 (CVCL_0062)

Cell line name MDA-MB-231
Synonyms MDA-MB 231; MDA.MB.231; MDA MB 231; MDA MB231; MDA Mb231; MDA-MB231; MDAMB-231; MDAMB231; MDA-231; MDA231; MB231; MD Anderson-Metastatic Breast-231
Accession CVCL_0062
Resource Identification Initiative To cite this cell line use: MDA-MB-231 (RRID:CVCL_0062)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: ENCODE project common cell types; tier 3.
Part of: ICBP43 breast cancer cell line panel.
Part of: JFCR39 cancer cell line panel.
Part of: JFCR45 cancer cell line panel.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: NCI-60 cancer cell line panel.
Registration: Chiron Master Culture Collection; CMCC 10583 (CMCC #10583).
Doubling time: 1.3 days (PubMed=9671407); 41.9 hours (NCI-DTP); 38 hours (ATCC); ~25-30 hours (DSMZ); ~38 hours (PBCF).
Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger).
Omics: Array-based CGH.
Omics: Cell surface proteome.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: miRNA expression profiling.
Omics: N-glycan profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Secretome proteome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: MDA-MD-231; In Cosmic 1071900 and Cosmic 1176602.
Misspelling: MDA-321; In GEO GSM459713.
Misspelling: MDA-MG-231; In PubMed=6582512.
Misspelling: MD-MB-231; In PRIDE PXD010634.
Misspelling: MD-MBA-231; Occasionally.
Sequence variations Heterozygous for BRAF p.Gly464Val (c.1391G>T) (PubMed=17088437).
Heterozygous for KRAS p.Gly13Asp (c.38G>A) (PubMed=17088437).
Homozygous for TP53 p.Arg280Lys (c.839G>A) (PubMed=16541312; PubMed=17088437; PubMed=18277095; PubMed=28889351).
HLA typing Source: PubMed=15748285
Class I
HLA-AA*02:01,02:17
HLA-BB*40:02,41:01
HLA-CC*02:02:02,17
Class II
HLA-DPDPB1*02:01:02,17:01
HLA-DQDQB1*02:02,03:01:01
HLA-DRDRB1*07:01,13:05

Source: PubMed=25960936
Class I
HLA-AA*02:17,02:01
HLA-BB*41:01,40:02
HLA-CC*17:01,02:02
Class II
HLA-DQDQA1*02:01,02:01
DQB1*03:04,03:04
HLA-DRDRB1*13:05,07:01
Disease Breast adenocarcinoma (NCIt: C5214)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_EQ20 (2LMP)CVCL_DP48 (MDA-BoM-1833)CVCL_4Y38 (MDA-MB-231 25PACR)
CVCL_4Y39 (MDA-MB-231 50PACR)CVCL_IN16 (MDA-MB-231 CMV)CVCL_IN17 (MDA-MB-231 ERalpha)
CVCL_IN15 (MDA-MB-231 ERalpha203/4/11)CVCL_IN18 (MDA-MB-231 ERbeta)CVCL_IN19 (MDA-MB-231 ERbetaDBD)
CVCL_DF47 (MDA-MB-231 NucLight Green)CVCL_DF48 (MDA-MB-231 NucLight Red)CVCL_RA90 (MDA-MB-231 shPARG)
CVCL_S031 (MDA-MB-231 SimpleCell O-GalNAc)CVCL_9U30 (MDA-MB-231-5a)CVCL_R956 (MDA-MB-231-BAG)
CVCL_JG53 (MDA-MB-231-Luc)CVCL_1D88 (MDA-MB-231-luc-D3H1)CVCL_D582 (MDA-MB-231-luc2)
CVCL_V403 (MDA-MB-231-MEK-R)CVCL_5J05 (MDA-MB-231-Red-FLuc)CVCL_5J06 (MDA-MB-231-Red-FLuc-GFP)
CVCL_1D91 (MDA-MB-231-tdTomato)CVCL_S511 (MDA-MB-231/5-FU)CVCL_5T76 (MDA-MB-231/B02)
CVCL_JZ03 (MDA-MB-231/GFP)CVCL_JZ04 (MDA-MB-231/GFP-RFP)CVCL_JZ05 (MDA-MB-231/Luc)
CVCL_4Z64 (MDA-MB-231/PacR)CVCL_JZ06 (MDA-MB-231/RFP)CVCL_4Z65 (MDA-MB-231DR)
CVCL_M354 (MDA-MB-231LLM)CVCL_4V67 (MDA231-DOX[r])CVCL_VR35 (MDA231-TGL)
Sex of cell Female
Age at sampling 51Y
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CLS; Cosmic-CLP; DSMZ; ECACC; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200; PubMed=28889351

Markers:
AmelogeninX
CSF1PO12,13
D13S31713
D16S53912
D18S5111,16
D19S43311,14
D21S1130,33.2 (CLS; PubMed=28889351)
33.2 (DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200)
D2S133820,21
D3S135816
D5S81812
D7S8208,9
D8S117913
FGA22,23
Penta D11,14
Penta E11
TH017,9.3
TPOX8,9
vWA15,18 (ATCC; Cosmic-CLP; DSMZ; ECACC; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200; PubMed=28889351)
15,19 (AddexBio; CLS)
Web pages https://de.wikipedia.org/wiki/MDA-MB-231_(Zelllinie)
https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
https://physics.cancer.gov/docs/bioresource/breast/NCI-PBCF-HTB26_MDA-MB-231_SOP-508.pdf
https://strap.nci.nih.gov/celline_detail.php?sample_id=2
http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=MDA-MB-231
http://genome.ucsc.edu/ENCODE/protocols/cell/human/MDA-MB-231_Struhl_protocol.pdf
http://lincs.hms.harvard.edu/resources/reagents/icbp43/
http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-394.html
http://tcpaportal.org/mclp/
https://www.phe-culturecollections.org.uk/media/133182/mda-mb-231-cell-line-profile.pdf
Publications

PubMed=4412247; DOI=10.1093/jnci/53.3.661
Cailleau R.M., Young R., Olive M., Reeves W.J. Jr.
Breast tumor cell lines from pleural effusions.
J. Natl. Cancer Inst. 53:661-674(1974)

PubMed=1000504
Lippman M., Bolan G., Huff K.
The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture.
Cancer Res. 36:4595-4601(1976)

PubMed=1000505
Lippman M., Bolan G., Huff K.
The effects of glucocorticoids and progesterone on hormone-responsive human breast cancer in long-term tissue culture.
Cancer Res. 36:4602-4609(1976)

PubMed=1000506
Lippman M., Bolan G., Huff K.
The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture.
Cancer Res. 36:4610-4618(1976)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=730202; DOI=10.1007/BF02616120
Cailleau R.M., Olive M., Cruciger Q.V.J.
Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.
In Vitro 14:911-915(1978)

PubMed=7000337
Brinkley B.R., Beall P.T., Wible L.J., Mace M.L., Turner D.S., Cailleau R.M.
Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro.
Cancer Res. 40:3118-3129(1980)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=7272986; DOI=10.1016/0165-4608(81)90057-1
Satya-Prakash K.L., Pathak S., Hsu T.C., Olive M., Cailleau R.M.
Cytogenetic analysis on eight human breast tumor cell lines: high frequencies of 1q, 11q and HeLa-like marker chromosomes.
Cancer Genet. Cytogenet. 3:61-73(1981)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K., Vistica D.T., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=8824553; DOI=10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#
Mullen P., Ritchie A., Langdon S.P., Miller W.R.
Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines.
Int. J. Cancer 67:816-820(1996)

PubMed=9671407; DOI=10.1038/sj.onc.1201814
Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
Oncogene 16:2865-2878(1998)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P., Iyer V., Jeffrey S.S., Van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=11687795; DOI=10.1038/ng754
Snijders A.M., Nowak N., Segraves R., Blackwood S., Brown N., Conroy J., Hamilton G., Hindle A.K., Huey B., Kimura K., Law S., Myambo K., Palmer J., Ylstra B., Yue J.P., Gray J.W., Jain A.N., Pinkel D., Albertson D.G.
Assembly of microarrays for genome-wide measurement of DNA copy number.
Nat. Genet. 29:263-264(2001)

PubMed=11697798; DOI=10.1359/jbmr.2001.16.11.2027
Peyruchaud O., Winding B., Pecheur I., Serre C.-M., Delmas P., Clezardin P.
Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.
J. Bone Miner. Res. 16:2027-2034(2001)

PubMed=12353263; DOI=10.1002/gcc.10107
Popovici C., Basset C., Bertucci F., Orsetti B., Adelaide J., Mozziconacci M.-J., Conte N., Murati A., Ginestier C., Charafe-Jauffret E., Ethier S.P., Lafage-Pochitaloff M., Theillet C., Birnbaum D., Chaffanet M.
Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.
Genes Chromosomes Cancer 35:204-218(2002)

PubMed=12661003; DOI=10.1002/gcc.10196
Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.-F., Schlag P.M., Scherneck S.
Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.
Genes Chromosomes Cancer 37:29-35(2003)

PubMed=12800145; DOI=10.1002/gcc.10218
Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Genes Chromosomes Cancer 37:333-345(2003)

PubMed=15677628; DOI=10.1093/carcin/bgi032
Gorringe K.L., Chin S.-F., Pharoah P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Carcinogenesis 26:923-930(2005)

PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11-11(2005)

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234
Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Mol. Cancer Ther. 4:399-412(2005)

PubMed=16142302; DOI=10.3892/ijo.27.4.881
de Longueville F., Lacroix M., Barbuto A.-M., Bertholet V., Gallo D., Larsimont D., Marcq L., Zammatteo N., Boffe S., Leclercq G., Remacle J.
Molecular characterization of breast cancer cell lines by a low-density microarray.
Int. J. Oncol. 27:881-892(2005)

PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 66:41-45(2006)

PubMed=16541312; DOI=10.1007/s10549-006-9186-z
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Breast Cancer Res. Treat. 99:97-101(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)

PubMed=18277095; DOI=10.4161/cbt.7.5.5712
Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T.
Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.
Cancer Biol. Ther. 7:699-708(2008)

PubMed=18386134; DOI=10.1007/s10585-008-9169-z
Hughes L., Malone C., Chumsri S., Burger A.M., McDonnell S.
Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity.
Clin. Exp. Metastasis 25:549-557(2008)

PubMed=18714363; DOI=10.1593/neo.08570
Kischel P., Guillonneau F., Dumont B., Bellahcene A., Stresing V., Clezardin P., De Pauw E.A., Castronovo V.
Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells.
Neoplasia 10:1014-1020(2008)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=19582160; DOI=10.1371/journal.pone.0006146
Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R.
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
PLoS ONE 4:E6146-E6146(2009)

CLPUB00423
Morrison B.J.
Breast cancer stem cells: tumourspheres and implications for therapy.
Thesis PhD (2010), Griffith University, Australia

PubMed=20070913; DOI=10.1186/1471-2407-10-15
Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M., Yamamoto S., Oka M., Hirano T., Sasaki K.
Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.
BMC Cancer 10:15-15(2010)

PubMed=21778573; DOI=10.3233/BD-2010-0307
Chavez K.J., Garimella S.V., Lipkowitz S.
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.
Breast Dis. 32:35-48(2010)

DOI=10.4172/2157-7145.S2-005
Fang R., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M., Hart R.P., Furtado M.R.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
J. Forensic Res. 2 Suppl. 2:5-5(2011)

PubMed=21378333
Ford C.H.J., Al-Bader M., Al-Ayadhi B., Francis I.
Reassessment of estrogen receptor expression in human breast cancer cell lines.
Anticancer Res. 31:521-527(2011)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017
Kong D., Yamori T.
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224
Marcotte R., Brown K.R., Suarez F., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23151021; DOI=10.1186/1471-2164-13-619
Grigoriadis A., Mackay A., Noel E., Wu P.J., Natrajan R., Frankum J., Reis-Filho J.S., Tutt A.
Molecular characterisation of cell line models for triple-negative breast cancers.
BMC Genomics 13:619-619(2012)

PubMed=23601657; DOI=10.1186/bcr3415
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33-R33(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.J., Bilke S., Walker R.L., Pineda M., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24009699; DOI=10.1371/journal.pone.0072704
Liu X., Nie H., Zhang Y.-B., Yao Y.-F., Maitikabili A., Qu Y.-P., Shi S.-L., Chen C.-Y., Li Y.
Cell surface-specific N-glycan profiling in breast cancer.
PLoS ONE 8:E72704-E72704(2013)

PubMed=24162158; DOI=10.1007/s10549-013-2743-3
Prat A., Karginova O., Parker J.S., Fan C., He X., Bixby L., Harrell J.C., Roman E., Adamo B., Troester M., Perou C.M.
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Breast Cancer Res. Treat. 142:237-255(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y., Mills G.B., Cho R.J., Collisson E.A., van't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20-20(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:E954893-E954893(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=26055192; DOI=10.1021/acs.jproteome.5b00375
Cifani P., Kirik U., Waldemarson S., James P.
Molecular portrait of breast-cancer-derived cell lines reveals poor similarity with tumors.
J. Proteome Res. 14:2819-2827(2015)

PubMed=26218769; DOI=10.1016/j.jchromb.2015.07.021
Willmann L., Schlimpert M., Halbach S., Erbes T., Stickeler E., Kammerer B.
Metabolic profiling of breast cancer: differences in central metabolism between subtypes of breast cancer cell lines.
J. Chromatogr. B 1000:95-104(2015)

PubMed=26649326; DOI=10.1016/j.dib.2015.09.039
Cox T.R., Schoof E.M., Gartland A., Erler J.T., Linding R.
Dataset for the proteomic inventory and quantitative analysis of the breast cancer hypoxic secretome associated with osteotropism.
Data Brief 5:621-625(2015)

PubMed=27331101; DOI=10.1016/j.dib.2016.05.040
Aumsuwan P., Khan S.I., Khan I.A., Walker L.A., Dasmahapatra A.K.
Gene expression profiling and pathway analysis data in MCF-7 and MDA-MB-231 human breast cancer cell lines treated with dioscin.
Data Brief 8:272-279(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20-20(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28889351; DOI=10.1007/s10549-017-4496-x
Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L., Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E., Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J., Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E., Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F., Lakhani S.R.
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
Breast Cancer Res. Treat. 167:289-301(2018)

Cross-references
Cell line collections AddexBio; C0006002/58
ATCC; CRL-12532 - Discontinued
ATCC; HTB-26
ATCC; CRM-HTB-26
BCRC; 60425
BCRJ; 0164
CLS; 300275/p536_MDA-MB-231
DSMZ; ACC-732
ECACC; 92020424
ICLC; HTL99004
IZSLER; BS TCL 223
KCB; KCB 200776YJ
KCLB; 30026
NCBI_Iran; C578
NCI-DTP; MDA-MB-231
Cell line databases/resources CLDB; cl3402
CLDB; cl3404
CLDB; cl3405
CLDB; cl4945
CCLE; MDAMB231_BREAST
CCRID; 3111C0001CCC000014
CCRID; 3131C0001000700104
Cosmic-CLP; 905960
GDSC; 905960
LINCS_HMS; 50058
LINCS_LDP; LCL-1461
Lonza; 815
SKY/M-FISH/CGH; 2815
TOKU-E; 2394
Ontologies BTO; BTO:0000815
CLO; CLO_0007634
EFO; EFO_0001209
MCCL; MCC:0000313
Biological sample resources BioSample; SAMN03472205
BioSample; SAMN05292460
Chemistry resources ChEMBL-Cells; CHEMBL3307960
ChEMBL-Targets; CHEMBL400
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM812
GEO; GSM2124
GEO; GSM50184
GEO; GSM50248
GEO; GSM69194
GEO; GSM155213
GEO; GSM185093
GEO; GSM185094
GEO; GSM274653
GEO; GSM344349
GEO; GSM344399
GEO; GSM350547
GEO; GSM378148
GEO; GSM388213
GEO; GSM459713
GEO; GSM481304
GEO; GSM587393
GEO; GSM587394
GEO; GSM750781
GEO; GSM799321
GEO; GSM799384
GEO; GSM820814
GEO; GSM820815
GEO; GSM820816
GEO; GSM847036
GEO; GSM847401
GEO; GSM844594
GEO; GSM844595
GEO; GSM887295
GEO; GSM888370
GEO; GSM967818
GEO; GSM1008905
GEO; GSM1053716
GEO; GSM1153390
GEO; GSM1172979
GEO; GSM1172889
GEO; GSM1181242
GEO; GSM1181365
GEO; GSM1214569
GEO; GSM1238120
GEO; GSM1374651
GEO; GSM1374652
GEO; GSM1401658
GEO; GSM1613823
GEO; GSM1670080
GEO; GSM1833624
GEO; GSM2095710
GEO; GSM2095711
GEO; GSM2124643
Metabolomic databases MetaboLights; MTBLS337
Other Wikidata; Q17577870
Polymorphism and mutation databases Cosmic; 687494
Cosmic; 871146
Cosmic; 875878
Cosmic; 877450
Cosmic; 894087
Cosmic; 897423
Cosmic; 904377
Cosmic; 905960
Cosmic; 934536
Cosmic; 944294
Cosmic; 974235
Cosmic; 991324
Cosmic; 997929
Cosmic; 1010924
Cosmic; 1018477
Cosmic; 1027053
Cosmic; 1044226
Cosmic; 1046950
Cosmic; 1047693
Cosmic; 1071900
Cosmic; 1092613
Cosmic; 1136369
Cosmic; 1152528
Cosmic; 1175833
Cosmic; 1176602
Cosmic; 1176636
Cosmic; 1183773
Cosmic; 1219444
Cosmic; 1287926
Cosmic; 1289395
Cosmic; 1305383
Cosmic; 1309003
Cosmic; 1312370
Cosmic; 1434952
Cosmic; 1436032
Cosmic; 1466805
Cosmic; 1477428
Cosmic; 1481426
Cosmic; 1524347
Cosmic; 1571793
Cosmic; 1609458
Cosmic; 1927242
Cosmic; 1945862
Cosmic; 1998455
Cosmic; 2009512
Cosmic; 2036667
Cosmic; 2164997
Cosmic; 2301528
Cosmic; 2318377
Cosmic; 2361355
Cosmic; 2560256
Proteomic databases PRIDE; PXD000239
PRIDE; PXD000397
PRIDE; PXD000691
PRIDE; PXD000914
PRIDE; PXD001553
PRIDE; PXD002192
PRIDE; PXD002649
PRIDE; PXD005942
PRIDE; PXD010634